• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Climate Change, Skin Health, and Dermatologic Disease: A Guide for the Dermatologist
AbstractClimate change has a pervasive impact on health and is of clinical relevance to every organ system. Climate change-related factors impact the skin ’s capacity to maintain homeostasis, leading to a variety of cutaneous diseases. Stratospheric ozone depletion has led to increased risk of melanoma and keratinocyte carcinomas due to ultraviolet radiation exposure. Atopic dermatitis, psoriasis, pemphigus, acne vulgaris, melasma, and photoaging ar e all associated with rising levels of air pollution. Elevated temperatures due to global warming induce disruption of the skin microbiome, thereby impacting atopic dermatiti...
Source: American Journal of Clinical Dermatology - June 20, 2023 Category: Dermatology Source Type: research

817 Ethanol induces skin hyperpigmentation in mice with aldehyde dehydrogenase 2 deficiency
Excessive alcohol consumption leads to alcohol use disorder. Alcohol is metabolized to acetaldehyde, which is then oxidized to acetic acid by aldehyde dehydrogenases (ALDH), a class of enzymes that facilitate the conversion of aldehydes to their corresponding acids. Among ALDHs, mitochondrial ALDH2 is the primary enzyme involved in the metabolism of acetaldehyde. In addition to its well-known role in ethanol metabolism, recent studies have suggested that ALDH2 dysfunction is associated with a variety of human diseases including cardiovascular diseases, diabetes, neurodegenerative diseases, stroke, cancer, anemia, pain, osteoporosis and aging.
Source: Journal of Investigative Dermatology - April 19, 2019 Category: Dermatology Authors: T. Yamauchi, A. Matsumoto, S. Ito, K. Wakamatsu, T. Suzuki, M. Fujita Tags: Pigmentation and Melanoma Source Type: research

Juvenile melanomas: Western Australian Melanoma Advisory Service experience.
CONCLUSIONS: Juvenile melanoma remains a rarity in Western Australia despite a very high incidence of adult melanoma. Unlike in adults, no definitive risk factors have been established. A significant proportion of this cohort had a pre-existing naevus and while most melanomas occurred in sun-exposed areas in light-skinned individuals the association between sunburn and melanoma was not strong. PMID: 28809039 [PubMed - as supplied by publisher]
Source: The Australasian Journal of Dermatology - August 15, 2017 Category: Dermatology Authors: Xu JX, Koek S, Lee S, Hanikeri M, Lee M, Beer T, Saunders C Tags: Australas J Dermatol Source Type: research

Juvenile melanomas: Western Australian Melanoma Advisory Service experience
ConclusionsJuvenile melanoma remains a rarity in Western Australia despite a very high incidence of adult melanoma. Unlike in adults, no definitive risk factors have been established. A significant proportion of this cohort had a pre‐existing naevus and while most melanomas occurred in sun‐exposed areas in light‐skinned individuals the association between sunburn and melanoma was not strong.
Source: Australasian Journal of Dermatology - May 1, 2017 Category: Dermatology Authors: Jie Xin Xu, Sharnice Koek, Samantha Lee, Mark Hanikeri, Mark Lee, Trevor Beer, Christobel Saunders Tags: Original Research Source Type: research

Biomarker value and pitfalls of serum S100B in the follow‐up of high‐risk melanoma patients
ConclusionsSerum S100B is a useful quantitative biomarker in routine follow‐up of high‐risk melanoma patients. While false‐negative results are frequent in patients with low tumor load, false‐positive results are associated with several comorbid diseases and warrant careful reevaluation.
Source: JDDG - January 27, 2016 Category: Dermatology Authors: Christoffer Gebhardt, Ramtin Lichtenberger, Jochen Utikal Tags: Original Article Source Type: research

Tildrakizumab (MK‐3222), an anti‐interleukin‐23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo‐controlled trial
ConclusionsTildrakizumab had treatment effects that were superior to placebo, maintained for 52 weeks of treatment, and persisted for 20 weeks after cessation. Tildrakizumab was generally safe and well tolerated. These results suggest that IL‐23p19 is a key target for suppressing psoriasis.
Source: British Journal of Dermatology - October 15, 2015 Category: Dermatology Authors: K. Papp, D. Thaçi, K. Reich, E. Riedl, R.G. Langley, J.G. Krueger, A.B. Gottlieb, H. Nakagawa, E.P. Bowman, A. Mehta, Q. Li, Y. Zhou, R. Shames Tags: Clinical Trials Source Type: research

PodMed: A Medical News Roundup From Johns Hopkins (with audio)
(MedPage Today) -- This week's topics include citrus and melanoma, a new oral medication for obesity, stroke treatment guidelines, and a vaccine for Helicobacter pylori.
Source: MedPage Today Dermatology - July 5, 2015 Category: Dermatology Source Type: news

Transient memory impairment and transient global amnesia induced by photodynamic therapy
This article is protected by copyright. All rights reserved.
Source: British Journal of Dermatology - June 30, 2015 Category: Dermatology Authors: M. Reinholz, M.V. Heppt, F. Hoffmann, N. Lummel, T. Ruzicka, P. Lehmann, C. Berking Tags: Case Report Source Type: research

Tildrakizumab (MK-3222), an Anti- IL-23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo- Controlled Trial.
CONCLUSIONS: Tildrakizumab demonstrated superior efficacy vs. placebo that was maintained up to 52 weeks of treatment and for an additional 20 weeks after cessation of study therapy. Tildrakizumab was generally safe and well tolerated. These results suggest that IL-23p19 is a key target for suppressing psoriasis. ClinicalTrials Registry # NCT01225731 This article is protected by copyright. All rights reserved. PMID: 26042589 [PubMed - as supplied by publisher]
Source: The British Journal of Dermatology - June 3, 2015 Category: Dermatology Authors: Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R Tags: Br J Dermatol Source Type: research

Tildrakizumab (MK‐3222), an Anti‐ IL‐23p19 Monoclonal Antibody, Improves Psoriasis in a Phase 2b Randomized Placebo‐ Controlled Trial
ConclusionsTildrakizumab demonstrated superior efficacy vs. placebo that was maintained up to 52 weeks of treatment and for an additional 20 weeks after cessation of study therapy. Tildrakizumab was generally safe and well tolerated. These results suggest that IL‐23p19 is a key target for suppressing psoriasis. ClinicalTrials Registry # NCT01225731This article is protected by copyright. All rights reserved.
Source: British Journal of Dermatology - June 1, 2015 Category: Dermatology Authors: K. Papp, D. Thaçi, K. Reich, E. Riedl, R.G. Langley, J.G. Krueger, A.B. Gottlieb, H. Nakagawa, E.P. Bowman, A. Mehta, Q. Li, Y. Zhou, R. Shames Tags: Original Article Source Type: research